Table 3b.
Baseline pre-existing brachyury-specific T-cell responses by intracellular cytokine staining assay
| Carcinoma | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CD4 | CD8 | |||||||||
| Pt | Cancer | Dose level | CD107a | IFNγ | IL2 | TNF | CD107a | IFNγ | IL2 | TNF |
| 2 | Ovarian | 1 | PRE | |||||||
| 15 | Breast | 2 | ||||||||
| 18 | Breast | 2 | ||||||||
| 25 | Breast | 2 | ||||||||
| 7 | Colon | 2 | ||||||||
| 17 | Colon | 2 | ||||||||
| 23 | Colon | 2 | PRE | PRE | ||||||
| 24 | Colon | 2 | ||||||||
| 11 | Lung | 2 | ||||||||
| 6 | Pancreatic | 2 | PRE | PRE | ||||||
| 22 | Prostate | 2 | PRE | PRE | PRE | |||||
| 27 | Breast | 3 | ||||||||
| 38 | Breast | 3 | PRE | PRE | PRE | PRE | PRE | |||
| 14 | Colon | 3 | PRE | |||||||
| 26 | Colon | 3 | PRE | PRE | ||||||
| 32 | Colon | 3 | PRE | |||||||
| 33 | Colon | 3 | ||||||||
| 28 | Lung | 3 | ||||||||
| 34 | Lung | 3 | ||||||||
| 36 | Lung | 3 | ||||||||
| 12 | Pancreatic | 3 | ||||||||
| 19 | Prostate | 3 | ||||||||
| 29 | Prostate | 3 | ||||||||
| Baseline response | Developed response | |
|---|---|---|
| Yes | No | |
| YES: 8/23 (35%) | 5/8 (63%) | 3/8 (37%) |
| NO: 15/23 (65%) | 13/15 (87%) | 2/15 (13%) |
| Chordoma | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CD4 | CD8 | |||||||||
| Pt | Cancer | Dose level | CD107a | IFNγ | IL2 | TNF | CD107a | IFNγ | IL2 | TNF |
| 1 | Chordoma | 1 | PRE | |||||||
| 3 | Chordoma | 1 | ||||||||
| 4 | Chordoma | 2 | PRE | PRE | ||||||
| 5 | Chordoma | 2 | ||||||||
| 8 | Chordoma | 2 | PRE | PRE | ||||||
| 9 | Chordoma | 2 | ||||||||
| 10 | Chordoma | 2 | PRE | PRE | PRE | |||||
| 16 | Chordoma | 3 | ||||||||
| 21 | Chordoma | 3 | ||||||||
| 30 | Chordoma | 3 | PRE | PRE | ||||||
| 37 | Chordoma | 3 | PRE | |||||||
| Baseline response | Developed response | |
|---|---|---|
| Yes | No | |
| YES: 6/11 (55%) | 5/6 (83%) | 1/6 (17%) |
| NO: 5/11 (45%) | 5/5 (100%) | 0/5 (0%) |